112
Views
25
CrossRef citations to date
0
Altmetric
Case Report

Atomoxetine-induced hepatitis in a child

, Pharm.D, , F.A.C.M.T , M.D. , F.A.C.E.P., , M.D., , M.D. & , F.A.A.A.S , Pharm.D. , M.S. , F.C.C.P.
Pages 51-55 | Received 10 Feb 2006, Accepted 03 May 2006, Published online: 07 Oct 2008

REFERENCES

  • Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25: 3065–3083
  • , DuffGCommittee on safety of medicine: Strattera (atomoxetine)—risk of hepatic disorders 2 February 2005. Accessed 23 June 2005. http://www.mhra.gov.uk/news/February/straterra_healthprof.pdf
  • , Eli Lilly and Company. Lilly news – financial news release. 18 April 2005. Accessed 23 June 2005. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=160474
  • 4. Eli Lilly and Company. Strattera® (atomoxetine) prescribing information, data on file. Indianapolis, IN, 2004.
  • Lee WM. Review article – drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474–485
  • Feldman M, Friedman LS, Sleisenger MH. Liver diseases caused by drugs, anesthetics, and toxins. In. Gastrointestinal and Liver Disease. W.B. Saunders Company, Philadelphia 2002; 1403–1447
  • Colle I, Naegels S, Hoorens A, Hautekeete M. Granulomatous hepatitis due to mebendazole. J Clin Gastroenterol 1999; 18: 44–48
  • Koppes GM, Arnett FC. Salicylate hepatotoxicity. Postgrad Med 1974; 56: 193–195
  • Danan G, Benichou C. Causality assessment of adverse reactions to drugs 1. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323–1330
  • Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf 2004; 3: 329–344
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245
  • Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003; 13: 53–63
  • De Leon J, Armstrong SC, Cozza KL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP 450 2C19. Psychosomatics 2006; 47: 75–85
  • Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, Desante KA. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98–107

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.